Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-02-27

AUTHORS

Maja Vimpolsek, Marie Gottar-Guillier, Emmanuel Rossy

ABSTRACT

OBJECTIVE: PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion. METHODS: Two batches of PF-SZ-IFX were reconstituted to a concentration of 10 mg/mL and subsequently diluted to 0.4 and 4.0 mg/mL, representing the clinically relevant range for intravenous infusion. Dilution was performed in polyethylene saline infusion bags, which are commonly used in clinical practice. To simulate product handling under worst-case conditions, reconstituted solutions were stored for up to 30 days at 5 ± 3 °C and up to 14 days at 25 ± 2 °C (60 ± 5% relative humidity); diluted solutions were stored for up to 30 days under the same sets of conditions. Physicochemical and biological stability were evaluated according to pH, osmolality, appearance, particulate content, protein concentration, proportions of molecular weight variants and charge variants and potency. Standard and state-of-the-art analytical techniques were employed, including imaged isoelectric focusing, size exclusion chromatography, reducing sodium dodecyl sulphate capillary electrophoresis and functional cell-based bioassay. RESULTS: Across batches and concentrations of PF-SZ-IFX, all parameters resided within the predefined acceptance criteria, including pH, osmolality, particulate content, clarity, protein concentration, molecular weight variants, charge variants and potency, for up to 30 days under both storage conditions tested (up to 14 days for reconstituted samples stored at 25 ± 2 °C). CONCLUSIONS: Physicochemical and biological analyses demonstrated that the infliximab biosimilar PF-SZ-IFX was not affected by extended storage of the diluted preparations used for intravenous infusion. More... »

PAGES

127-140

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-019-0264-1

DOI

http://dx.doi.org/10.1007/s40268-019-0264-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112400547

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30810925


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medicinal and Biomolecular Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biosimilar Pharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Packaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Stability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Storage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infliximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Biopharmaceutical Product and Process Development, Drug Product Analytics, Novartis, Lek d. d., Menges, Slovenia", 
          "id": "http://www.grid.ac/institutes/grid.457257.6", 
          "name": [
            "Biopharmaceutical Product and Process Development, Drug Product Analytics, Novartis, Lek d. d., Menges, Slovenia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vimpolsek", 
        "givenName": "Maja", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biopharmaceutical Product and Process Development, Analytical Development and Characterization, Novartis, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Biopharmaceutical Product and Process Development, Analytical Development and Characterization, Novartis, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottar-Guillier", 
        "givenName": "Marie", 
        "id": "sg:person.01033432351.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033432351.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biopharmaceutical Product and Process Development, Analytical Characterization, Novartis, Hexal AG, Oberhaching, Germany", 
          "id": "http://www.grid.ac/institutes/grid.476364.4", 
          "name": [
            "Biopharmaceutical Product and Process Development, Analytical Characterization, Novartis, Hexal AG, Oberhaching, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossy", 
        "givenName": "Emmanuel", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12325-016-0403-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041653106", 
          "https://doi.org/10.1007/s12325-016-0403-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-018-1646-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105875897", 
          "https://doi.org/10.1186/s13075-018-1646-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-27", 
    "datePublishedReg": "2019-02-27", 
    "description": "OBJECTIVE: PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion.\nMETHODS: Two batches of PF-SZ-IFX were reconstituted to a concentration of 10\u00a0mg/mL and subsequently diluted to 0.4 and 4.0\u00a0mg/mL, representing the clinically relevant range for intravenous infusion. Dilution was performed in polyethylene saline infusion bags, which are commonly used in clinical practice. To simulate product handling under worst-case conditions, reconstituted solutions were stored for up to 30\u00a0days at 5\u2009\u00b1\u20093\u00a0\u00b0C and up to 14\u00a0days at 25\u2009\u00b1\u20092\u00a0\u00b0C (60\u2009\u00b1\u20095% relative humidity); diluted solutions were stored for up to 30\u00a0days under the same sets of conditions. Physicochemical and biological stability were evaluated according to pH, osmolality, appearance, particulate content, protein concentration, proportions of molecular weight variants and charge variants and potency. Standard and state-of-the-art analytical techniques were employed, including imaged isoelectric focusing, size exclusion chromatography, reducing sodium dodecyl sulphate capillary electrophoresis and functional cell-based bioassay.\nRESULTS: Across batches and concentrations of PF-SZ-IFX, all parameters resided within the predefined acceptance criteria, including pH, osmolality, particulate content, clarity, protein concentration, molecular weight variants, charge variants and potency, for up to 30\u00a0days under both storage conditions tested (up to 14\u00a0days for reconstituted samples stored at 25\u2009\u00b1\u20092\u00a0\u00b0C).\nCONCLUSIONS: Physicochemical and biological analyses demonstrated that the infliximab biosimilar PF-SZ-IFX was not affected by extended storage of the diluted preparations used for intravenous infusion.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-019-0264-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "sodium dodecyl sulfate capillary electrophoresis", 
      "biological stability", 
      "art analytical techniques", 
      "size exclusion chromatography", 
      "exclusion chromatography", 
      "capillary electrophoresis", 
      "analytical techniques", 
      "cell-based bioassays", 
      "molecular weight variants", 
      "preparation", 
      "biological analysis", 
      "isoelectric focusing", 
      "stability", 
      "weight variants", 
      "storage conditions", 
      "following preparation", 
      "infusion bags", 
      "PF-06438179/GP1111", 
      "relevant range", 
      "extended storage", 
      "chromatography", 
      "concentration", 
      "solution", 
      "protein concentration", 
      "pH", 
      "batch", 
      "product handling", 
      "potency", 
      "electrophoresis", 
      "bioassay", 
      "dilution", 
      "conditions", 
      "storage", 
      "acceptance criteria", 
      "content", 
      "range", 
      "mL", 
      "focusing", 
      "technique", 
      "particulate content", 
      "state", 
      "parameters", 
      "handling", 
      "analysis", 
      "use", 
      "same set", 
      "biosimilars", 
      "appearance", 
      "variants", 
      "bags", 
      "set", 
      "proportion", 
      "days", 
      "infliximab biosimilar", 
      "osmolality", 
      "clarity", 
      "worst-case conditions", 
      "IFX", 
      "intravenous infusion", 
      "infusion", 
      "criteria", 
      "clinical practice", 
      "practice", 
      "PF-SZ", 
      "GP1111", 
      "polyethylene saline infusion bags", 
      "saline infusion bags", 
      "imaged isoelectric focusing", 
      "dodecyl sulphate capillary electrophoresis", 
      "sulphate capillary electrophoresis", 
      "functional cell-based bioassay", 
      "infliximab biosimilar PF-SZ", 
      "biosimilar PF-SZ", 
      "Extended In-Use Stability", 
      "In-Use Stability", 
      "Infliximab Biosimilar PF-06438179/GP1111 Following Preparation", 
      "Biosimilar PF-06438179/GP1111 Following Preparation", 
      "PF-06438179/GP1111 Following Preparation", 
      "GP1111 Following Preparation"
    ], 
    "name": "Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion", 
    "pagination": "127-140", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112400547"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-019-0264-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30810925"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-019-0264-1", 
      "https://app.dimensions.ai/details/publication/pub.1112400547"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_822.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-019-0264-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-019-0264-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-019-0264-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-019-0264-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-019-0264-1'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      22 PREDICATES      116 URIs      104 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-019-0264-1 schema:about N3d36142c46ec42b1bed0045bd806cc53
2 N49d148e844aa4dffb45bdcd7b74892c3
3 N5cbaeaff2bac46e4853da7a15094d5a5
4 N91cc6addc82a43d7a1a404dd8041bcab
5 Naaff47656a27458b92ae0eab7d971726
6 Naf12ea02642744709b86532a2b236847
7 Nbdf9097413e84c40a0a86c8d6ec71ccd
8 anzsrc-for:03
9 anzsrc-for:0304
10 anzsrc-for:11
11 anzsrc-for:1115
12 schema:author Nbd451ecd657f44deb293f9ad00032f61
13 schema:citation sg:pub.10.1007/s12325-016-0403-9
14 sg:pub.10.1186/s13075-018-1646-4
15 schema:datePublished 2019-02-27
16 schema:datePublishedReg 2019-02-27
17 schema:description OBJECTIVE: PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion. METHODS: Two batches of PF-SZ-IFX were reconstituted to a concentration of 10 mg/mL and subsequently diluted to 0.4 and 4.0 mg/mL, representing the clinically relevant range for intravenous infusion. Dilution was performed in polyethylene saline infusion bags, which are commonly used in clinical practice. To simulate product handling under worst-case conditions, reconstituted solutions were stored for up to 30 days at 5 ± 3 °C and up to 14 days at 25 ± 2 °C (60 ± 5% relative humidity); diluted solutions were stored for up to 30 days under the same sets of conditions. Physicochemical and biological stability were evaluated according to pH, osmolality, appearance, particulate content, protein concentration, proportions of molecular weight variants and charge variants and potency. Standard and state-of-the-art analytical techniques were employed, including imaged isoelectric focusing, size exclusion chromatography, reducing sodium dodecyl sulphate capillary electrophoresis and functional cell-based bioassay. RESULTS: Across batches and concentrations of PF-SZ-IFX, all parameters resided within the predefined acceptance criteria, including pH, osmolality, particulate content, clarity, protein concentration, molecular weight variants, charge variants and potency, for up to 30 days under both storage conditions tested (up to 14 days for reconstituted samples stored at 25 ± 2 °C). CONCLUSIONS: Physicochemical and biological analyses demonstrated that the infliximab biosimilar PF-SZ-IFX was not affected by extended storage of the diluted preparations used for intravenous infusion.
18 schema:genre article
19 schema:inLanguage en
20 schema:isAccessibleForFree true
21 schema:isPartOf N02029d854ce9453dbc5fdbfb5a36cc1d
22 N841c8e3b027d44c8a18c699ce79fa395
23 sg:journal.1020803
24 schema:keywords Biosimilar PF-06438179/GP1111 Following Preparation
25 Extended In-Use Stability
26 GP1111
27 GP1111 Following Preparation
28 IFX
29 In-Use Stability
30 Infliximab Biosimilar PF-06438179/GP1111 Following Preparation
31 PF-06438179/GP1111
32 PF-06438179/GP1111 Following Preparation
33 PF-SZ
34 acceptance criteria
35 analysis
36 analytical techniques
37 appearance
38 art analytical techniques
39 bags
40 batch
41 bioassay
42 biological analysis
43 biological stability
44 biosimilar PF-SZ
45 biosimilars
46 capillary electrophoresis
47 cell-based bioassays
48 chromatography
49 clarity
50 clinical practice
51 concentration
52 conditions
53 content
54 criteria
55 days
56 dilution
57 dodecyl sulphate capillary electrophoresis
58 electrophoresis
59 exclusion chromatography
60 extended storage
61 focusing
62 following preparation
63 functional cell-based bioassay
64 handling
65 imaged isoelectric focusing
66 infliximab biosimilar
67 infliximab biosimilar PF-SZ
68 infusion
69 infusion bags
70 intravenous infusion
71 isoelectric focusing
72 mL
73 molecular weight variants
74 osmolality
75 pH
76 parameters
77 particulate content
78 polyethylene saline infusion bags
79 potency
80 practice
81 preparation
82 product handling
83 proportion
84 protein concentration
85 range
86 relevant range
87 saline infusion bags
88 same set
89 set
90 size exclusion chromatography
91 sodium dodecyl sulfate capillary electrophoresis
92 solution
93 stability
94 state
95 storage
96 storage conditions
97 sulphate capillary electrophoresis
98 technique
99 use
100 variants
101 weight variants
102 worst-case conditions
103 schema:name Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
104 schema:pagination 127-140
105 schema:productId N13ad5e57fe5441638830f39e3d12513b
106 N31ec07607a864dfc8335cb8cda363dd1
107 N3efdc3610f22400f9538dae9afc74ce4
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112400547
109 https://doi.org/10.1007/s40268-019-0264-1
110 schema:sdDatePublished 2021-12-01T19:46
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N645b6f5d8906477b882eafdad01c26dc
113 schema:url https://doi.org/10.1007/s40268-019-0264-1
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N02029d854ce9453dbc5fdbfb5a36cc1d schema:issueNumber 2
118 rdf:type schema:PublicationIssue
119 N13ad5e57fe5441638830f39e3d12513b schema:name doi
120 schema:value 10.1007/s40268-019-0264-1
121 rdf:type schema:PropertyValue
122 N31ec07607a864dfc8335cb8cda363dd1 schema:name pubmed_id
123 schema:value 30810925
124 rdf:type schema:PropertyValue
125 N3d36142c46ec42b1bed0045bd806cc53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Biosimilar Pharmaceuticals
127 rdf:type schema:DefinedTerm
128 N3efdc3610f22400f9538dae9afc74ce4 schema:name dimensions_id
129 schema:value pub.1112400547
130 rdf:type schema:PropertyValue
131 N3f20f34a0ca64cfea40975ed915da6ff rdf:first Nb777ec9a7f8848feb8f7115b0d893c48
132 rdf:rest rdf:nil
133 N42ff100cae394ff58eba279c4f947784 rdf:first sg:person.01033432351.80
134 rdf:rest N3f20f34a0ca64cfea40975ed915da6ff
135 N49d148e844aa4dffb45bdcd7b74892c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Time Factors
137 rdf:type schema:DefinedTerm
138 N5cbaeaff2bac46e4853da7a15094d5a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Drug Packaging
140 rdf:type schema:DefinedTerm
141 N645b6f5d8906477b882eafdad01c26dc schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N841c8e3b027d44c8a18c699ce79fa395 schema:volumeNumber 19
144 rdf:type schema:PublicationVolume
145 N91cc6addc82a43d7a1a404dd8041bcab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Infusions, Intravenous
147 rdf:type schema:DefinedTerm
148 Naaff47656a27458b92ae0eab7d971726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Drug Storage
150 rdf:type schema:DefinedTerm
151 Naf12ea02642744709b86532a2b236847 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Drug Stability
153 rdf:type schema:DefinedTerm
154 Nb777ec9a7f8848feb8f7115b0d893c48 schema:affiliation grid-institutes:grid.476364.4
155 schema:familyName Rossy
156 schema:givenName Emmanuel
157 rdf:type schema:Person
158 Nbd451ecd657f44deb293f9ad00032f61 rdf:first Ne8a2a12867ad45d5a046d43d5ecf4a28
159 rdf:rest N42ff100cae394ff58eba279c4f947784
160 Nbdf9097413e84c40a0a86c8d6ec71ccd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Infliximab
162 rdf:type schema:DefinedTerm
163 Ne8a2a12867ad45d5a046d43d5ecf4a28 schema:affiliation grid-institutes:grid.457257.6
164 schema:familyName Vimpolsek
165 schema:givenName Maja
166 rdf:type schema:Person
167 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
168 schema:name Chemical Sciences
169 rdf:type schema:DefinedTerm
170 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medicinal and Biomolecular Chemistry
172 rdf:type schema:DefinedTerm
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
177 schema:name Pharmacology and Pharmaceutical Sciences
178 rdf:type schema:DefinedTerm
179 sg:journal.1020803 schema:issn 1174-5886
180 1179-6901
181 schema:name Drugs in R&D
182 schema:publisher Springer Nature
183 rdf:type schema:Periodical
184 sg:person.01033432351.80 schema:affiliation grid-institutes:grid.419481.1
185 schema:familyName Gottar-Guillier
186 schema:givenName Marie
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033432351.80
188 rdf:type schema:Person
189 sg:pub.10.1007/s12325-016-0403-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041653106
190 https://doi.org/10.1007/s12325-016-0403-9
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/s13075-018-1646-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105875897
193 https://doi.org/10.1186/s13075-018-1646-4
194 rdf:type schema:CreativeWork
195 grid-institutes:grid.419481.1 schema:alternateName Biopharmaceutical Product and Process Development, Analytical Development and Characterization, Novartis, Basel, Switzerland
196 schema:name Biopharmaceutical Product and Process Development, Analytical Development and Characterization, Novartis, Basel, Switzerland
197 rdf:type schema:Organization
198 grid-institutes:grid.457257.6 schema:alternateName Biopharmaceutical Product and Process Development, Drug Product Analytics, Novartis, Lek d. d., Menges, Slovenia
199 schema:name Biopharmaceutical Product and Process Development, Drug Product Analytics, Novartis, Lek d. d., Menges, Slovenia
200 rdf:type schema:Organization
201 grid-institutes:grid.476364.4 schema:alternateName Biopharmaceutical Product and Process Development, Analytical Characterization, Novartis, Hexal AG, Oberhaching, Germany
202 schema:name Biopharmaceutical Product and Process Development, Analytical Characterization, Novartis, Hexal AG, Oberhaching, Germany
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...